Rhythm Pharmaceuticals to Announce Topline Results from Phase 2 Trial of Oral MC4R Agonist Bivamelagon for Acquired Hypothalamic Obesity

Reuters

Jul 09

Rhythm Pharmaceuticals to Announce Topline Results from Phase 2 Trial of Oral MC4R Agonist Bivamelagon for Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. has announced plans to present topline results from a Phase 2 trial evaluating their investigational oral MC4R agonist, bivamelagon, in patients with acquired hypothalamic obesity. The results will be disclosed during a live conference call and webcast scheduled for 8:00 a.m. ET on Wednesday, July 9, 2025. The trial is a randomized, placebo-controlled study designed to assess the efficacy of bivamelagon. The webcast of the conference call will be available on the company's website, with an archived version accessible for at least 30 days following the call.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9490393-en) on July 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550578989"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550578989\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550578989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550578989","market":"nz","top_or_hot":-1,"title":"Rhythm Pharmaceuticals to Announce Topline Results from Phase 2 Trial of Oral MC4R Agonist Bivamelagon for Acquired Hypothalamic Obesity","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rhythm Pharmaceuticals to Announce Topline Results from Phase 2 Trial of Oral MC4R Agonist Bivamelagon for Acquired Hypothalamic Obesity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rhythm Pharmaceuticals, Inc. has announced plans to present topline results from a Phase 2 trial evaluating their investigational oral MC4R agonist, bivamelagon, in patients with acquired hypothalamic obesity. The results will be disclosed during a live conference call and webcast scheduled for 8:00 a.m. ET on Wednesday, July 9, 2025. The trial is a randomized, placebo-controlled study designed to assess the efficacy of bivamelagon. The webcast of the conference call will be available on the company's website, with an archived version accessible for at least 30 days following the call.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RYTM\">Rhythm Pharmaceuticals Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9490393-en) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Pharmaceuticals to Announce Topline Results from Phase 2 Trial of Oral MC4R Agonist Bivamelagon for Acquired Hypothalamic Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Pharmaceuticals to Announce Topline Results from Phase 2 Trial of Oral MC4R Agonist Bivamelagon for Acquired Hypothalamic Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-09 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Rhythm Pharmaceuticals to Announce Topline Results from Phase 2 Trial of Oral MC4R Agonist Bivamelagon for Acquired Hypothalamic Obesity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Rhythm Pharmaceuticals, Inc. has announced plans to present topline results from a Phase 2 trial evaluating their investigational oral MC4R agonist, bivamelagon, in patients with acquired hypothalamic obesity. The results will be disclosed during a live conference call and webcast scheduled for 8:00 a.m. ET on Wednesday, July 9, 2025. The trial is a randomized, placebo-controlled study designed to assess the efficacy of bivamelagon. The webcast of the conference call will be available on the company's website, with an archived version accessible for at least 30 days following the call.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RYTM\">Rhythm Pharmaceuticals Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9490393-en) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL8QL4r3:1","article_id":"2550578989","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550578989","pubTimestamp":1752004871,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rhythm Pharmaceuticals to Announce Topline Results from Phase 2 Trial of Oral MC4R Agonist Bivamelagon for Acquired Hypothalamic Obesity. Rhythm Pharmaceuticals, Inc. has announced plans to present topline results from a Phase 2 trial evaluating their investigational oral MC4R agonist, bivamelagon, in patients with acquired hypothalamic obesity. The results will be disclosed during a live conference call and webcast scheduled for 8:00 a.m. ET on Wednesday, July 9, 2025. The trial is a randomized, placebo-controlled study designed to assess the efficacy of bivamelagon. The webcast of the conference call will be available on the company's website, with an archived version accessible for at least 30 days following the call.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","RYTM":"Rhythm Pharmaceuticals Inc.","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Rhythm Pharmaceuticals将公布口服MC4R激动剂Bivamelagon治疗获得性下丘脑肥胖的2期试验的主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"RYTM":0.9},"content_text":"Rhythm Pharmaceuticals to Announce Topline Results from Phase 2 Trial of Oral MC4R Agonist Bivamelagon for Acquired Hypothalamic Obesity\n    \n\n        Rhythm Pharmaceuticals, Inc. has announced plans to present topline results from a Phase 2 trial evaluating their investigational oral MC4R agonist, bivamelagon, in patients with acquired hypothalamic obesity. The results will be disclosed during a live conference call and webcast scheduled for 8:00 a.m. ET on Wednesday, July 9, 2025. The trial is a randomized, placebo-controlled study designed to assess the efficacy of bivamelagon. The webcast of the conference call will be available on the company's website, with an archived version accessible for at least 30 days following the call.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9490393-en) on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}